ArticleJHEP reports : innovation in hepatology2023

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022).

Sabrina Sidali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.